Interim Management Statement

WORLDWIDE HEALTHCARE TRUST PLC                         

    Interim Management Statement - 3 months to 31 December 2011 (unaudited)    

Worldwide Healthcare Trust PLC invests worldwide in pharmaceutical, 
biotechnology and related companies in the healthcare sector with the objective
of achieving a high level of capital growth.

During the 3 month period ended 31 December 2011 the Company's fully diluted
net asset value per share total return was 7.6% and the share price total
return was 5.8%, compared to a rise of 9.3% in the Company's benchmark, the
MSCI World Health Care Index measured in sterling terms on a total return
basis. The Company's performance in the period was helped by strong returns
from emerging biotechnology holdings, including Pharmasset which agreed a
takeover approach from Gilead Sciences at an 89% premium to its closing share
price on 18 November. Negative contributors to performance included the
Company's Japanese holdings, which fell sharply in October and also Chinese
biopharmaceutical company 3SBio which was a victim of the general weakness that
has affected emerging market stocks and also concerns about pricing pressure on
drugs in China.

During the three-month period a total of 49,070 shares were repurchased to be
held in treasury at an average discount of 10.2% and 10,813 new shares were
issued, as a result of holders of subscription shares exercising their
subscription rights, raising £69,000 of additional funds for the Company.

Since the period end, to 2 February 2012, a further 234,231 shares have been
bought back for treasury by the Company at an average discount of 8.0% and
56,150 subscription shares were bought back for cancellation. 467,487 new
shares were allotted on 2 February, as a result of holders of subscription
shares exercising their subscription rights, raising £2,983,000 of additional
funds for the Company. As at 2 February 2012 there were 43,681,449 shares in
issue excluding 308,301 shares held in treasury.

In the period from 31 December 2011 to 2 February 2012, the Company's fully
diluted net asset value per share total return was 2.8% and the share price
total return was 4.0% compared to a rise of 1.1% in the Company's benchmark.

Trust Characteristics

                            31 December 2011         30 September 2011         
                                                                               
Number of holdings                     63                        67            
                                                                               
Net assets (£m)                      357.8                     328.8           
                                                                               
Yield                                 2.0%                      2.2%           
                                                                               
Gearing (AIC basis)                   107                       117            
                                                                               
Share price (p)                      733.00                    693.00          
                                                                               
NAV (p) -undiluted                   823.50                    756.18          
                                                                               
NAV (p) diluted: sub shares          795.23                    738.17          
                                                                               
NAV (p) - fully diluted for          795.14                    738.14          
                                                                               
sub shares and treasury                                                        
shares                                                                         
                                                                               
(Discount)/premium                  (11.0%)                    (8.4%)          
(undiluted)                                                                    
                                                                               
(Discount/premium(diluted -          (7.8%)                    (6.1%)          
sub shares)                                                                    
                                                                               
(Discount)/premium (fully   (7.8%)                             (6.1%)          
diluted)                                                                       
                                                                               
Subscription share price    82.50                              72.25           
(p)                                                                            

Source: Frostrow Capital LLP

10 Largest Investments

Name                                 % of                       % of           
                                                                               
                                   portfolio                 portfolio         
                                                                               
                              at 31 December 2011       at 30 September 2011   
                                                                               
Novartis                              6.4                       6.3            
                                                                               
Pfizer                                6.2                       5.2            
                                                                               
Roche                                 5.6                       5.4            
                                                                               
Mitsubishi Tanabe Pharma              4.4                       4.8            
                                                                               
Merck & Co                            4.0                       3.5            
                                                                               
Allergan                              3.2                       3.1            
                                                                               
Gilead Sciences                       2.9                       2.8            
                                                                               
Bristol-Myers Squibb                  2.9                       2.7            
                                                                               
United Health                         2.9                       2.7            
                                                                               
Wellpoint                             2.6                       2.6            
                                                                               
                                     41.1                       39.1           

Source: Frostrow Capital LLP

Sector Analysis

                                     % of                       % of           
                                                                               
                                   portfolio                 portfolio         
                                                                               
                              at 31 December 2011       at 30 September 2011   
                                                                               
Large capitalisation                 64.8                       65.4           
                                                                               
Small capitalisation                 35.2                       34.6           
                                                                               
Total                                100.0                     100.0           

Source: Frostrow Capital LLP

Geographical Analysis

                                     % of                       % of           
                                                                               
                                  portfolio                  portfolio         
                                                                               
                             at 31 December 2011        at 30 September 2011   
                                                                               
North America                        65.8                       65.1           
                                                                               
Europe                               22.1                       20.6           
                                                                               
Far East                             11.5                       13.3           
                                                                               
Israel                               0.6                        1.0            
                                                                               
Total                               100.0                      100.0           

Source: Frostrow Capital LLP

Total Return Performance to 31 December 2011

                3 Months        1 Year          3 Years         5 Years        
                                                                               
Share price     +5.8%           +6.5%           +36.6%          +60.0%         
                                                                               
NAV Fully       +7.6%           +7.3%           +35.0%          +64.1%         
diluted                                                                        
                                                                               
Benchmark*      +9.3%           +11.1%          +25.9%          +50.0%         

Source: NAV (total return; fully diluted) and Share Price (total return)
Morningstar. Benchmark - Thomson Reuters

*Benchmark - With effect from 1 October 2010, the performance of the Company is
measured against the MSCI World Health Care Index on a total return, sterling
adjusted basis. Prior to this date, performance was measured against the
Datastream World Pharmaceutical and Biotechnology Index measured in sterling
terms on a total return basis. Historic data, therefore, consists of a blended
figure containing both indices.

Past performance is not a guide to future performance.

This Interim Management Statement has been prepared solely to provide
information to meet the requirements of the UK Listing Authority's Disclosure
and Transparency Rules.

This Interim Management Statement is available on the Company's website 
www.worldwidewh.com.

The Company's net asset value per share is announced daily and is available,
together with the share price, on the Company's website www.worldwidewh.com and
on the TrustNet website at www.trustnet.com

SEDOL Codes:

Shares - 0338530

Subscription Shares - B3VMCB0

ISIN:

Shares - GB0003385308

Subscription Shares - GB00B3VMCB07

For further information contact: Mark Pope on 0203 008 4913

Frostrow Capital LLP

Company Secretary

3 February 2012